ADVANCED OR METASTATIC SOLID TUMORS
Clinical trials for ADVANCED OR METASTATIC SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new ADVANCED OR METASTATIC SOLID TUMORS trials appear
Sign up with your email to follow new studies for ADVANCED OR METASTATIC SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug called KGX101, alone or with another drug envafolimab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body processes the drugs. A…
Matched conditions: ADVANCED OR METASTATIC SOLID TUMORS
Phase: PHASE1 • Sponsor: Kangabio AUSTRALIA LTD PTY • Aim: Disease control
Last updated May 26, 2026 03:25 UTC
-
New drug WTX-330 shows promise in early trial for tough cancers
Disease control OngoingThis study tests an experimental drug called WTX-330 in about 100 adults with advanced solid tumors or non-Hodgkin lymphoma that hasn't responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. Researchers will also monitor si…
Matched conditions: ADVANCED OR METASTATIC SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Werewolf Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:22 UTC
-
Could a simple shot replace IV drips for some cancer patients?
Disease control OngoingThis early-stage study looks at whether a shot under the skin (subcutaneous injection) of pembrolizumab works as well as the standard IV version for people with advanced solid tumors. About 72 adults will receive different doses to measure how much drug gets into the blood and to…
Matched conditions: ADVANCED OR METASTATIC SOLID TUMORS
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 03:05 UTC
-
New drug duo targets hard-to-treat cancers with RAS mutation
Disease control OngoingThis early-stage study tests two drugs, naporafenib and trametinib, in people with advanced solid tumors that have a specific RAS Q61X mutation and have stopped responding to other treatments. The goal is to see if the combination can shrink tumors and control the disease. About …
Matched conditions: ADVANCED OR METASTATIC SOLID TUMORS
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug combo tested for tough-to-treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called ERAS-601, alone or with other cancer treatments, in adults with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety, find the best dose, and see if the drug can shrink tum…
Matched conditions: ADVANCED OR METASTATIC SOLID TUMORS
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated May 18, 2026 12:09 UTC